Last week, Dr. Jofre Ferrer-Dalmau, CEO, presented Bioeclosion at the UAB Investment forum, as closure event of Arquímedes acceleration program. Dr. Ferrer-Dalmau explained Bioeclosion technology, goals and potentiality at a dozen of investors and VC managers. It was highlithed the recently opened Pre-Series A round to complete the development of Bioeclosion MVP.
As a UAB spin-off company, Bioeclosion was invited to join Arquímedes program aiming to help accelerate the company to fulfill its mission and goals. The program combined specialist workshops, personalized mentoring sessions, and an investment forum.
The event was located at Casa de Convalescència, Hospital de Sant Pau, Barcelona, on 13th December 2023.
